Concomitant administration of Kaltrofen and acetosal and other protein-binding drugs (eg, anticoagulants, sulphonylurea, hydantoins) can decrease ketoprofen protein-binding and increase ketoprofen plasma clearance. Although the clinically significant change is not adequate, concurrent use of these drugs is not recommended.
Hydrochlorothiazide given concomitantly with Kaltrofen increases the risk of developing renal function failure.
Co-administration of Kaltrofen with methotrexate must be avoided because ketoprofen will increase the toxicity of methotrexate. Kaltrofen may inhibit tubular secretion of methotrexate.
Complication of warfarin treatment and use of Kaltrofen may cause bleeding in the gastrointestinal tract. Therefore, concomitant administration of these 2 drugs requires close monitoring.
NSAID increases steady-state plasma lithium levels. It is recommended that plasma lithium level be monitored when Kaltrofen is co-administered with lithium.
Probenecid increases free and bound Kaltrofen by reducing the plasma clearance. Therefore, concurrent administration of these 2 drugs is not recommended.
Gel: No interaction of KALTROFEN gel with other drugs have been reported, but it is necessary to monitor patients under treatment with coumarinic substances.